Latest News for PPTDF
PeptiDream (OTCMKTS:PPTDF - Get Free Report) is anticipated to post its resultson Wednesday, August 12th. Analysts expect PeptiDream to post earnings of ($0.0196) per share and revenue of $34.8960 million for the quarter. PeptiDream Price Performance Shares of OTCMKTS PPTDF opened at $6.00 on Monday. The firm's 50-day moving average price is $6.19 and its
KAWASAKI, Japan--(BUSINESS WIRE)-- #DrugDelivery--The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.
KAWASAKI, Japan--(BUSINESS WIRE)-- #Cancer--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA.
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PPTDF.
Senate Trading
No Senate trades found for PPTDF.
U.S. House Trading
No House trades found for PPTDF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.